Benefits of CyberKnife(R) Lung Radiosurgery Treatments Emphasized During Europe's Largest Congress in Radiation Oncology

Conference Presentations Highlight CyberKnife Motion Management Capabilities in Treatment of Lung Cancer

SUNNYVALE, California, September 17, 2010 - Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of
radiosurgery, announced today that for the first time in Europe the company
showcased its latest offering, the CyberKnife VSI System, at ESTRO 29; the
Annual Congress of the European Society for Therapeutic Radiology and
Oncology in Barcelona, Spain. Also featured at this meeting were multiple
presentations demonstrating this system's best-in-class motion management
capabilities for lung cancer care.

During a well-attended symposium on motion management in lung
radiosurgery chaired by Pr. Volker Budach, M.D., Ph.D., Charite -
Universitatsmedizin, Berlin, physics and clinical findings were presented by
representatives from two CyberKnife sites: Erasmus MC - Daniel den Hoed
Cancer Centre in Rotterdam, Netherlands and Centre Antoine Lacassagne in
Nice, France. Clinical research presented during the symposium demonstrated
the benefits of CyberKnife radiosurgery in the treatment of primary early
stage and metastatic lung cancer, including excellent disease control and
preservation of quality of life. Enabling these outcomes are the CyberKnife
System's unique motion management capabilities including the Synchrony(R)
Respiratory Tracking System, which enables real-time tracking and correction
for tumors that move with respiration.

"The Synchrony System is unique in its ability to correct for changes in
a patient's pattern of breathing in real-time," said Dr. Joost Nuyttens,
M.D., Ph.D., Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam. "This
allows us to significantly reduce delivery margins while eliminating the need
for abdominal compression or breath-holding techniques."

In addition, two CyberKnife users were recognized for outstanding
research. The ACCURAY-ESTRO Award, which for the last several years has
recognized radiotherapy professionals for original research in the field of
high precision radiotherapy, was awarded to Dr. Joost Nuyttens (Rotterdam),
for his lecture entitled "Outcome of Four-dimensional Stereotactic
Radiotherapy for centrally located Lung Tumors". Within the National Young
Scientist Session, the first prize was won by Jean-Emmanuel Bibault,
Resident, Centre Oscar Lambret, Lille for his oral poster reporting on
outcomes obtained using the fiducial-free Xsight(R) Lung Tracking System
titled, "Early efficacy and toxicity evaluation of CyberKnife Xsight Lung."

"Both of these awards highlight industry-leading approaches to
non-invasive lung cancer treatment using CyberKnife radiosurgery," said
Vittorio Puppo, General Manager, Accuray EIMEA (Europe, India, Middle East,
Asia). "We congratulate our productive and dedicated users on this fine honor
and thank them for their important research contributions."

More than 20 posters and oral presentations during this year's ESTRO
meeting highlighted the continued expansion of extracranial radiosurgery
applications with the CyberKnife System, including presentations on lung,
liver, prostate, spine, pancreas, and head and neck cancer.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body
non-invasively. Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in real-time throughout
the treatment. This enables the CyberKnife System to deliver high-dose
radiation with pinpoint precision, which minimizes damage to surrounding
healthy tissue and eliminates the need for invasive head or body
stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a
global leader in the field of radiosurgery dedicated to providing an improved
quality of life and a non-surgical treatment option for those diagnosed with
cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery
System, which extends the benefits of radiosurgery to include extracranial
tumors, including those in the spine, lung, prostate, liver and pancreas. To
date, the CyberKnife System has been used to treat more than 95,000 patients
worldwide and currently more than 206 systems have been installed in leading
hospitals in the Americas, Europe and Asia. For more information, please
visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve
risks and uncertainties, including uncertainties associated with the medical
device industry. Except for the historical information contained herein, the
matters set forth in this press release, including statements relating to
clinical efficacy, clinical benefits, clinical acceptance, clinical
publications, and clinical results are forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements speak only as of the date the
statements are made and are based on information available at the time those
statements are made and/or management's good faith belief as of that time
with respect to future events. You should not put undue reliance on any
forward-looking statements. Important factors that could cause actual
performance and results to differ materially from the forward-looking
statements we make include: market acceptance of products; competing
products, the combination of our products with complementary technology; and
other risks detailed from time to time under the heading "Risk Factors" in
our report on Form 10-K for the 2010 fiscal year which has been filed with
the Securities and Exchange Commission on August, 31, 2010. The Company's
actual results of operations may differ significantly from those contemplated
by such forward-looking statements as a result of these and other factors. We
assume no obligation to update forward-looking statements to reflect actual
performance or results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent required by
applicable securities laws.

Sancie Nakarat, Manager, EU Marketing, +33-0-6-81-36-84-34, snakarat at accuray.com, or Stephanie Tomei, +1-408-789-4234, stomei at accuray.com, both of Accuray Incorporated